Bioptimus is developing what it describes as the first universal AI foundation model for biology, integrating biological data spanning molecules, cells, tissues, and whole organisms. Rather than building narrow task-specific tools, the company trains large multimodal models natively across modalities and scales so they can learn the underlying dynamics of human biology and predict what happens next.
The company's flagship releases include H-Optimus, a foundation model for computational pathology, and M-Optimus, an integrated multimodal model. These models target applications in drug discovery, biomarker identification, and clinical diagnostics, and Bioptimus reports they rank at the top of independent benchmarks.
Founded in 2024 in Paris by a team led by CEO Jean-Philippe Vert, formerly Chief R&D Officer at Owkin and a research lead at Google Brain, Bioptimus assembled frontier ML researchers and biologists from institutions including Google DeepMind, Meta, MIT, ETH Zurich, and Cambridge. The company says its platforms are used by over 1,000 institutions and trusted by 16 of the top 20 pharmaceutical companies.
Bioptimus emerged from stealth with a $35 million seed round led by Sofinnova Partners. In January 2025 it announced a $41 million Series A led by Cathay Innovation, with participation from Sofinnova Partners, Bpifrance, Andera Partners, and Hitachi Ventures, bringing total funding to $76 million.
The funding supports expansion of its multimodal AI platform, integration of more diverse data sources, and strategic partnerships with pharmaceutical and biotech companies.